Lipocine Completes Scheduled Independent Data Safety Monitoring Board Review Of Ongoing Phase 3 Clinical Trial evaluating LPCN 1154 For Rapid Relief Treatment Of PPD.
Benzinga Newsdesk 9 months ago
BiotechNewsGeneral
Company on track to report topline results early in the second quarter of 2026Second planned Data and Safety Monitoring Board (DSMB) meeting evaluated all available safety data for the 82 randomizedNo drug
- Company on track to report topline results early in the second quarter of 2026
- Second planned Data and Safety Monitoring Board (DSMB) meeting evaluated all available safety data for the 82 randomized
- No drug discontinuations, excessive sedation, loss of consciousness, or drug-related SAEs reported
- Study is no longer screening new participants
- No drug discontinuations, excessive sedation, loss of consciousness, or drug-related SAEs reported